Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 18/20 | 0.56 |
| ▸ | PRKD2 | Q9BZL6 | 10/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13087722 | 1.00 | PRKCZ (0.56) | PRKCZPRKD2AXLCYP1A2CYP2C19 | |
| SCHEMBL2422864 | 0.94 | CYP1A2 (0.52) | PRKCZPRKD2AXLCYP1A2CYP2C19 | |
| SCHEMBL2424276 | 0.85 | PRKCZ (0.45) | PRKCZPRKD2CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL2425114 | 0.85 | CYP1A2 (0.44) | PRKCZPRKD2CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL2422828 | 0.84 | ROCK2 (0.48) | PRKCZPRKD2CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL12327397 | 0.82 | PRKCZ (0.48) | PRKCZPRKD2AXLCYP1A2CYP2C19 | |
| SCHEMBL15172413 | 0.82 | PRKCZ (0.43) | PRKCZPRKD2CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL2434116 | 0.81 | ROCK2 (0.44) | PRKCZPRKD2CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL3628367 | 0.81 | ROCK2 (0.47) | PRKCZPRKD2CYP1A2CYP2C19HSD17B10 | |
| SCHEMBL15172428 | 0.80 | PRKCZ (0.46) | PRKCZPRKD2CYP1A2CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | PRKCZ 272/4885PRKD2 49/4885AXL 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.